1-3 of 3
David Cohan
Close
Sort by
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Jonathan E Brammer, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Eric D Jacobsen, Giuseppe Gritti, Debra Litwak, David Cohan, Danica J Katz, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz
Journal: Blood
Blood (2021) 138 (Supplement 1): 2456.
https://doi.org/10.1182/blood-2021-148939
Published: 2021
Journal Articles

TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)

Vladimir I. Vorobyev, Dok Hyun Yoon, Maciej Kaźmierczak, Sebastian Grosicki, Corrado Tarella, Angelo Genua, Jin Seok Kim, Debra Litwak, David Cohan, Ian W. Flinn, Pier Luigi Zinzani, Leo I. Gordon
Journal: Blood
Blood (2021) 138 (Supplement 1): 3545.
https://doi.org/10.1182/blood-2021-147564
Published: 2021
Journal Articles

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Joshua Richter, Jacob P. Laubach, Steve Stricker, Fredrik H. Schjesvold, David Cohan, Anna Sureda, Ewa Lech-Marańda, Meral Beksac, Vania Hungria, Meletios A. Dimopoulos, Ajai Chari, Paul G. Richardson, Philippe Moreau
Journal: Blood
Blood (2021) 138 (Supplement 1): 3759.
https://doi.org/10.1182/blood-2021-153694
Published: 2021